| President and
CEO, Cerimon Pharmaceuticals, Inc. Founded Cerimon
Pharmaceuticals, Inc, an MPM Capital portfolio company
in January 2005. Cerimon focuses on marketed or late
stage specialty pharmaceuticals. Prior to joining Cerimon,
Paul was President and Chief Business Officer of ARIAD
Pharmaceuticals, Inc, a NASDAQ oncology company based
in Cambridge, MA. In 2002 Paul joined the Sprout Group,
the venture affiliate of Credit Suisse First Boston
in New York, where he was a Partner for healthcare
technology investments.
Prior to joining Sprout, Paul spent four years at Novartis,
most recently as Senior Vice President and Head of Global
Search and Evaluation, Business Development and Licensing
for Novartis Pharma AG. At Novartis, he was responsible
for the creation of Novartis Pharmaceuticals' disease
area strategy, as well as establishing a dedicated function
focused on the identification and evaluation of new opportunities
for the company. Prior to this, Paul set up a new department,
Early Commercial Development, in order to ensure the
differential competitive advantage of Novartis' pipeline.
In the 1990's, Paul held senior management positions
at biotechnology firms, including Millipore Corporation,
where he led the Applied Microbiology Strategic Business
Unit, creating joint ventures with other biotechnology
firms and strategic collaborations with several pharmaceutical
companies. Previously, he held managerial positions in
healthcare marketing at Zymark Corporation and Genex
Corporation. Paul received his BS in molecular biology
and his MS in Neuroscience at the University of Maryland
School of Medicine. |
